DFDA

Methylphenidate Extended-Release

Treatment for Amphetamine Use Disorders

Typical Dosage: 36-72mg ER daily

Effectiveness
30%
Safety Score
45%
Clinical Trials
18
Participants
1.6K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
36-72mg ER daily
Time to Effect
Weeks
Treatment Duration
12-24 weeks
Evidence Quality
LOW
Confidence Score
45%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$500
Monitoring:$300
Side Effect Mgmt:$100
Total Annual:$900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$3,600
Cost per Remission
$9,000
Methylphenidate Extended-Release Outcomes

for Amphetamine Use Disorders

Efficacy Outcomes
Overall Effectiveness
+30%
Response Rate
+25%
Remission Rate
+10%
Common Side Effects
Insomnia
+25%
Anxiety
+20%
Decreased appetite
+15%
Increased heart rate/blood pressure
+8%
Nervousness
+12%

Sources:

nih.gov
researchgate.net
frontiersin.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov